SNP Schneider-Neureither & Partner SE header image

SNP Schneider-Neureither & Partner SE

SHF

Equity

ISIN DE0007203705 / Valor 1060617

Xetra (2025-11-17)
EUR 75.20-1.05%

SNP Schneider-Neureither & Partner SE
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

SNP Schneider-Neureither & Partner SE is a leading provider of software solutions and services for digital transformation and data migration. The company specializes in helping organizations streamline their processes in finance and accounting through the implementation of SAP systems, particularly S/4HANA. SNP's expertise lies in harmonizing multiple SAP systems and processes into a centralized S/4HANA system, defining standard templates, and reducing internal developments to a minimum. With a focus on efficiency and innovation, SNP assists clients in achieving their goals of modernizing and optimizing their financial and accounting operations.

Summarized from source with an LLMView SourceSector: Technology

Latest Results (08.11.2025):

SNP Schneider-Neureither & Partner SE reported strong financial results for the third quarter of 2025, demonstrating robust growth across key performance metrics. The firm’s order entry increased by 9% to €81.6 million, while revenue rose by 11% to €74.3 million. Notably, EBIT nearly doubled, registering a 91% increase to reach €15.6 million, accompanied by a significant improvement in EBIT margin. These results, underpinned by performance in the software and partner segments, have reinforced the company's raised full-year guidance for 2025.

Solid Order Growth

In Q3 2025, SNP Schneider-Neureither & Partner SE solidified its robust performance with a 9% increase in order entry, reaching €81.6 million, which reflects enhanced demand and a positive order-to-sales dynamic.

Revenue and Profitability Upsurge

The company saw an 11% uplift in revenue to €74.3 million, with EBIT nearly doubling (up 91% to €15.6 million). This performance boosted the EBIT margin by 8.8 percentage points to 21.0%, underscoring improved operational efficiencies.

Segment and Strategic Highlights

SNP’s software and partner business segments were the primary drivers of these results, with significant growth in order entries and revenues across both divisions, illustrating the firm’s dynamic approach to digital transformation and data management services.

Revised Full-Year Guidance

Buoyed by these solid quarterly results, SNP Schneider-Neureither & Partner SE confirmed its raised guidance for 2025, projecting higher ranges for both revenue and EBIT for the full fiscal year.

Summarized from source with an LLMView Source

Key figures

41.9%1Y
294%3Y
48.0%5Y

Performance

19.3%1Y
27.7%3Y
34.9%5Y

Volatility

Market cap

635 M

Market cap (USD)

Daily traded volume (Shares)

1,576

Daily traded volume (Shares)

1 day high/low

62.4 / 61

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Oracle Corp
Oracle Corp Oracle Corp Valor: 959184
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.34%USD 219.86
Pegasystems Inc
Pegasystems Inc Pegasystems Inc Valor: 503997
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.87%USD 54.65
Blueprint Medicines Corp
Blueprint Medicines Corp Blueprint Medicines Corp Valor: 27670715
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 129.46
Halozyme Therapeutics Inc
Halozyme Therapeutics Inc Halozyme Therapeutics Inc Valor: 1814799
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.76%USD 70.56
Nutanix Inc
Nutanix Inc Nutanix Inc Valor: 30912711
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.99%USD 64.60
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc Tarsus Pharmaceuticals Inc Valor: 57410241
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.71%USD 74.17
Flywire Corp
Flywire Corp Flywire Corp Valor: 111444572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.51%USD 13.57
Sezzle Inc
Sezzle Inc Sezzle Inc Valor: 129105133
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.24%USD 50.97
PAR Technology Corporation
PAR Technology Corporation PAR Technology Corporation Valor: 960461
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.66%USD 36.70
Toast Inc
Toast Inc Toast Inc Valor: 113470913
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.31%USD 34.71